Zhang Financial LLC Lowers Stock Holdings in Gilead Sciences, Inc. $GILD

Zhang Financial LLC trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 50.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,944 shares of the biopharmaceutical company’s stock after selling 1,965 shares during the period. Zhang Financial LLC’s holdings in Gilead Sciences were worth $216,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Smallwood Wealth Investment Management LLC bought a new stake in shares of Gilead Sciences during the first quarter valued at approximately $25,000. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Activest Wealth Management increased its position in shares of Gilead Sciences by 2,837.5% during the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 227 shares in the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $27,000. Finally, Colonial Trust Advisors increased its position in shares of Gilead Sciences by 304.3% during the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 213 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 2.1%

Shares of Gilead Sciences stock opened at $117.88 on Wednesday. The company’s fifty day simple moving average is $115.51 and its 200-day simple moving average is $111.33. The stock has a market capitalization of $146.27 billion, a PE ratio of 23.48, a P/E/G ratio of 0.83 and a beta of 0.34. Gilead Sciences, Inc. has a 1-year low of $86.08 and a 1-year high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $295,200.00. Following the transaction, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. The trade was a 1.57% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the transaction, the insider owned 114,168 shares in the company, valued at approximately $13,532,333.04. This trade represents a 19.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 61,500 shares of company stock worth $7,142,140 in the last 90 days. 0.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research report on Friday, July 25th. BMO Capital Markets raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Daiwa America raised shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 19th. Finally, Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.61.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.